CONGRESS OF THE LEBANESE UROLOGY SOCIETY. In collaboration with

Size: px

Start display at page:

Download "CONGRESS OF THE LEBANESE UROLOGY SOCIETY. In collaboration with"

Alfred Wood
5 years ago
Views:

1 CONGRESS OF THE LEBANESE UROLOGY SOCIETY In collaboration with 4-6 OCTOBER, 2018 HILTON HABTOOR- BEIRUT - LEBANON CME CREDITS

Welcome Letter Dear Colleagues, It is my great pleasure to welcome you to our 10 th CONGRESS of LEBANESE UROLOGY SOCIETY held in Hilton Habtoor on October 4 th to 6 th, 2018.

2 Welcome Letter Dear Colleagues, It is my great pleasure to welcome you to our 10 th CONGRESS of LEBANESE UROLOGY SOCIETY held in Hilton Habtoor on October 4 th to 6 th, The starting point of all achievements in life is the strong desire mixed by faith, planning and perseverance. When I was elected president of the society I chose Our Slogan Better communication and better collaboration, this was my strong desire that I believed in. This is why we started strengthening our international relationship with AFU, EAU, AAU and SIU as well as our national relationship with the Orders of Nurses and physiotherapists, LSMO, LIFE and Faculties of medicine of all universities in Lebanon. And here we will shall gather in a multidisciplinary conference rich in both international and national outstanding gallery of speakers from Europe, France and USA that will participate and share with us the most significant advances in our profession. Our program includes as well nursing and physiotherapy sessions that will help us understand and manage better our urological patients. We do have a great team who is working to make this a truly memorable meeting. I am looking forward to meeting you this October! Walid Alame, MD LUS President

3 LUS President Walid Alame President of the Congress Salim Salhab Organizing Committee Walid Alame Sani Beydoun Joseph Daccache Mohamed Hejase Fouad Khoury Elie Nemr Nehme Raad Pierre Sarkis Akram Sinno Chadi Waked

4 Thursday, October 4 th, :00-14:05 Introduction and welcoming by President of LUS Walid Alame 14:05-16:00 Session I: Nursing in Urology in Collaboration with the Order of Nurses in Lebanon Bladder Cancer: What Nurses Need to Know for an Integrated Care Prostate Cancer Nursing Management to Provide Quality Care Urolithiasis Nursing Management & Interventions Understanding Renal Function Tests Decreasing Cauti: Performance Improvement in Caring for Indwelling Urinary Catheters 15:50-16:00 Sahar Atieh Dina Moutran Charbel Zaccour Hassan Haballah Battoul Baalbaki 16:00-18:00 Session II: Physiotherapy in Urology in Collaboration with the Order of Physiotherapists in Lebanon Les modalités de la Rééducation Pelvi-Perinéale: Chez l Homme Chez la Femme Chez l Enfant Chez les Personnes Âgées 17:45-18:00 Nehme Nehme Madame Martine Cornillet-Bernard Nehme Nehme Madame Martine Cornillet-Bernard

5 Friday, October 5 th, 2018 Programme de la Journée Francophone AFU-SLU / Simultaneous Translation 08:00-09:00 Registration and Welcoming by the President of the LUS 09:00-10:15 Session I: Calcul 09:00-09:30 09:30-10:00 10:00-10:15 Walid Alame Moderators: Imad Farhat - Hadi Mawlawi - Jawad Feghali - Zahi Abou Rjeili Ureteroscopie Souple Calcul Urétéral: Traitement Médical, LEC vs Ureteroscopie 10:15-10:30 Pause Café Sponsored by Janssen Paul Méria Paul Méria 10:30-12:10 Session II: Prostate Moderators: Elie Nemr - Alain Khalaf - Mohamed Fayad 10:30-11:00 11:00-11:30 11:30-11:40 11:40-12:10 Traitements Mini-Invasifs de l HBP Cancer Prostatique: Dépistage et Diagnostic Moderator: Selim Zeineh Non-Metastatic Castration-Resistant Prostate Cancer: A Modern Perspective Symposium Sponsored by Janssen 12:10-13:00 Cérémonie d Ouverture Richard Mallet Pierre Mongiat-Artus Stephane Oudard 13:00-14:00 Déjeuner 14:00-16:40 Session III: Post Nap Session Moderators: Adib Ziadeh - Bernard Faraj - Guy Houkayem 14:00-14:30 The Role of Mirabegron in Managing Overactive Bladder Xavier Gamé Symposium Sponsored by Astellas 14:30-15:00 15:00-15:30 Hyperactivité et Hypoactivité Vesicale: Nouveautés en 2018 Supported by Astellas Nouveautés en Andrologie: Dysfonction Érectile, Peyronnie Xavier Gamé Antoine Faix 15:30-16:00 Recent Approaches to Managing ED with BPH Raja Khauli Symposium Sponsored by Lilly 16:00-16:30 16:30-16:40 CAT Devant les Petites Masses Rénales Arnaud Méjean

6 Saturday, October 6 th, 2018 in Collaboration with LSMO 08:30-09:00 Registration and Welcoming by the President of the LUS Walid Alame 09:00-10:20 Morning Session: Updates on Prostate Cancer 09:00-09:20 09:20-09:40 09:40-10:10 10:10-10:20 10:20-10:40 Coffee Break Moderators: Antoine Kassis - Fadi Saadeh - Ghazi Sakr Updates in the Management of Oligometastatic Prostate Cancer Role of Active Surveillance in Prostate Cancer Complex Cases: Prostate Cancer - Panelists: Elie Nemr, Alexandre de la Taille, George Farha, Deborah Mukherji, Georges Nawfal Alexandre de la Taille Alexandre de la Taille Raja Khauli 10:40-11:10 Moderator: Walid Alame Recent Update in mcrpc Management Symposium Sponsored by Astellas Alexandre de la Taille 11:10-13:30 Abstract Presentations 13:30-14:30 Lunch Break 14:30-15:50 Afternoon Session: Updates on Bladder Cancer Moderators: Wassim Wazzan - Nizar Bitar - Khalil Armach 14:30-14:50 14:50-15:20 15:20-15:40 T1 high Grade disease: The Real Threat Role of Immunotherapy in the Management of Bladder Cancer Complex Cases - Panelists: Roger Khater, Arnulf Stenzl, Arnulf Stenzl Arnulf Stenzl Michel Jabbour 15:40-15:50 Georges Assaf, Fares Azouri 15:50-17:10 Post Nap Session: Updates in Renal Cell Carcinoma Moderators: Gaby Kamel - Maroun Moukarzel - Rami Nasr 15:50-16:10 16:10-16:30 16:30-17:00 17:00-17:10 Adjuvant Therapy in Localized Renal Cell Carcinoma Cytoreductive Nephrectomy Complex Cases - Panelists: Mohamed Moussa, Jose Karam, Joseph Kattan Jose Karam Jose Karam Gaby Kamel

REGISTRATION FEES Lebanese Urologist $50 Foreigner Participants $300 Residents and Students Nurses Physiotherapist Free of Charge Free of Charge Free of Charge

7 REGISTRATION FEES Lebanese Urologist $50 Foreigner Participants $300 Residents and Students Nurses Physiotherapist Free of Charge Free of Charge Free of Charge Registration Fees Includes: Access to Scientific Sessions and Exhibition Area Congress Printing Materials Certificate of Attendance CME Accreditation Coffee Breaks and Lunches

8 We would like to thank the below sponsors for their contribution to the success of its annual congress Organized by: LEBANON 4 th Floor, Qubic Center Daoud Ammoun Street Horsh Tabet - Sin El Fil P.O. Box: Beirut Tel: /1/2/3 Mobile: UAE DMCC Business Centre Almas Tower Jumeirah Lakes Dubai, United Arab Emirates Unit No: 3820 Mobile:

Time for life SINCE 2011 ZYTIGA as first-line therapy in mcrpc and mhspc delivers remarkable overall survival benefits without

4 months median life extension vs prednisone alone in post-adt (HR 0.81; 95% CI 0.70 0.93; P=0.0033) **2 4.

0001) 3 FIRST IN NEWLY DIAGNOSED HIGH-RISK mhspc* 1 Superior median overall survival vs ADT alone (HR 0.62; 95% CI 0.51 0.76; P<0.

deprivation therapy * ZYTIGA approved for mcrpc post-chemotherapy in September 2011, mcrpc post-adt in January 2013 and for newly

** Asymptomatic or mildly symptomatic patients with mcrpc post-adt Median time not reached for ZYTIGA group References: 1.

9 Time for life SINCE 2011 ZYTIGA as first-line therapy in mcrpc and mhspc delivers remarkable overall survival benefits without compromising quality of life, so your patients can stay active for longer. FIRST NOVEL HORMONAL AGENT IN mcrpc* months median life extension vs prednisone alone in post-adt (HR 0.81; 95% CI ; P=0.0033) **2 4.6 months median life extension in post-chemotherapy patients (HR 0.74; 95% CI ; P<0.0001) 3 FIRST IN NEWLY DIAGNOSED HIGH-RISK mhspc* 1 Superior median overall survival vs ADT alone (HR 0.62; 95% CI ; P<0.001) 4 mcrpc=metastatic castration-resistant prostate cancer; mhspc=metastatic hormone-sensitive prostate cancer; ADT=androgen deprivation therapy * ZYTIGA approved for mcrpc post-chemotherapy in September 2011, mcrpc post-adt in January 2013 and for newly diagnosed high-risk mhspc in January ** Asymptomatic or mildly symptomatic patients with mcrpc post-adt Median time not reached for ZYTIGA group References: 1. ZYTIGA (abiraterone acetate) summary of product characteristics. Nov Ryan CJ, et al. Lancet Oncol 2015; 16: Fizazi K, et al. Lancet Oncol2012;13: Fizazi K, et al. N Engl J Med2017;377: FOR MAXIMUM IMPACT, USE ZYTIGA PLUS PREDNISONE FIRST-LINE IN mcrpc AND mhspc

CONGRESS OF THE LEBANESE UROLOGY SOCIETY In collaboration with

CONGRESS OF THE LEBANESE UROLOGY SOCIETY CONGRESS OF THE LEBANESE UROLOGY SOCIETY In collaboration with 4-6 OCTOBER, 2018 HILTON HABTOOR- BEIRUT - LEBANON Thursday, October 4, 2018 14:00-14:05 Introduction